Study
| Randomised, triple-blind, phase 3 trial |
| Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC |
| Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles |
Efficacy
| mDFS: 53.6 m vs 42.0 m (HR 0.76 [95% CI 0.63–0.91], p=0.0014) |
| mDFS: NR vs NR in the PD-L1 TPS of 50% or greater population (HR 0.82 [95% CI 0.57–1.18]; p=014). |
| 3 year OS: 82% vs %80 |
Safety
| Any grade AEs: 96% vs 91% |
| Grade ≥3 AEs: 34.7% vs 26.8% |
| Discontination due to adverse events: 20% vs 6% |
| Death due to adverse events: 2% vs 1% |
Lancet Oncol. 2022 Sep 9;S1470-2045(22)00518-6.
http://doi.org/10.1016/s1470-2045(22)00518-6
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
